sales@theinsightpartners.com
+1-646-491-9876 +44-20-8125-4005

Antibody Drug Conjugates Market Scope And Analysis

  • Report Code : TIPRE00003494
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 293
Buy Now

Antibody Drug Conjugates Market Analysis and Scope 2021-2031

Buy Now

Antibody Drug Conjugates Market Report Antibody Drug Conjugates Market Size and Share Antibody Drug Conjugates Market Scope and Analysis

Antibody Drug Conjugates Market Report Scope

Report Attribute Details
Market size in 2023 US$ 8,105.65 Million
Market Size by 2031 US$ 38,077.45 Million
Global CAGR (2023 - 2031) 21.3%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Technology
  • Cleavable Linker
  • Non-cleavable Linker
By Application
  • Blood Cancer
  • Brain Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
By Target
  • HER2
  • CD22
  • CD30
By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • ADC Therapeutics SA
  • Pfizer Inc
  • F Hoffmann La Roche Ltd
  • Daiichi Sankyo Co Ltd
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • RemeGen Co Ltd
  • Takeda Pharmaceutical Co Ltd